Summary
The effects of short- and long-term administration of nifedipine on serum lipids, lipoproteins, and apolipoproteins (apo) were studied. Administration of nifedipine capsule for 4 months significantly decreased triglycerides and increased the HDL2 cholesterol and the HDL2/HDL3 cholesterol ratio. No significant changes in serum lipids and lipoproteins were observed during short-term therapy with slow-release nifedipine tablets. Following administration of tablets for 24 months, the LDL/HDL cholesterol ratio, apo B, and apo B/apo A-I ratio increased at 12 months, but reverted to baseline values at 24 months. Apo E levels were decreased significantly at 24 months. No significant changes were noted in total cholesterol, triglyceride, HDL cholesterol, HDL2,3 cholesterol, apo A-I, apo A-II, apo C-II, or apo C-III levels during long-term therapy with slow-release nifedipine tablets. These results indicate that nifedipine has a neutral or even favorable effect on lipoprotein metabolism. However, a prospective well-controlled study would be required to finally establish this effect. This finding strengthens the indications for using nifedipine as a first-line drug in the long-term treatment of hypertension.
Similar content being viewed by others
References
Olivari MJ, Bartorelli C, Polsese A, et al. Treatment of hypertension with nifedipine, a calcium antagonistic agent.Circulation 1979;59:1059–1062.
Henry PD, Comparative pharmacology of calcium antagonists: Nifedipine, verapamil and diltiazem.Am. J Cardiol 1980;46:1047–1058.
Hugenholtz PG, Michels HR, Serruys PW, Brower PW, Nifedipine in the treatment of unstable angina, coronary spasm and myocardial ischemia.Am J Cardiol 1981;47:163–173.
Weidmann P, Uehlinger DE, Gerber A. Antihypertensive treatment and serum lipoproteins.J Hypertens 1985;3:297–306.
Vessby B, Abelin J, Finnson M, et al. Effects of nifedipine treatment on carbohydrate and lipoprotein metabolism.Curr Ther Res 1983;33:1075–1080.
Ohman KP, Weiner L, von Schenck H, Karlberg BE. Antihypertensive and metabolic effects of nifedipine and labetalol alone and in combination in primary hypertension.Eur J Clin Pharmacol 1985;29:149–154.
Pasanisi F, Ferrara AL, Iovine C, Mancini M. Effects of nifedipine on insulin secretion and plasma lipids in hypertensive patients.Curr Ther Res 1986;39:894–899.
Lehtonen A, Tanskanen A, Lehto H, Jarvensiven P. The effect of nifedipine on plasma lipids in patients with essential hypertension.Int J Clin Pharmacol Ther Toxicol 1986;24:357–358.
Schulte KL, Meyer-Sabllek WA, Haertenberger A, et al. Antihypertensive and metabolic effects of diltiazem and nifedipine.Hypertension 1986;8:859–865.
Sasaki J, Arakawa K. Effect of nidedipine on serum lipids, lipoproteins, and apolipoproteins in patients with essential hypertension.Curr Ther Res 1987;41:845–851.
Poll PE, Seagren SC, Sable AF. Effects of diltiazem on serum lipids, exercise performance and blood pressure: Randomized, double-blind, placebo-controlled evaluation for systemic hypertension.Am J Cardiol 1985;56:86H-91H.
Lewis GRJ, Long-term results with verapamil in essential hypertension and its influence on serum lipids.Am J Cardiol 1986;57:35D-38D.
Ishida N, Matsuo R, Migita T, et al.. Effects of nicardipine HCl on serum lipids and blood pressure.J Jpn Atheroscler Soc 1984;12:833–838.
Allain CC, Poon LS, Chan CS, et al. Enzymatic determination of total serum cholesterol.Clin Chem 1974;20:470–475.
Eggstein M, Kreutz FH. Eine neue Bestimmung der Neutralfette im Blutserum und Gewebe. I. Mitt. Prinzip. Durchfuhrung und Besprechung des Methode.Klin Wochenschr 1966;44:262.
Goto Y, Akanuma Y, Harano Y, et al.. Determination by the SRID method of normal values of serum apolipoproteis (A-I, A-II, B, C-II, C-III and E) in normolipidemic healthy Japanese subjects.J Clin Biochem Nutr 1986;1:73–88.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sasaki, J., Arakawa, K. Effects of short- and long-term administration of nifedipine on serum lipoprotein metabolism in patients with mild hypertension. Cardiovasc Drug Ther 4 (Suppl 5), 1033–1035 (1990). https://doi.org/10.1007/BF02018313
Issue Date:
DOI: https://doi.org/10.1007/BF02018313